Adrenoleukodystrophy
(Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H1 2018
Global
Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide
Adrenoleukodystrophy - Pipeline Review, H1 2018, provides an overview of the
Adrenoleukodystrophy (Genetic Disorders) pipeline landscape.
"Adrenoleukodystrophy
is a disorder that occurs most often in males. It mainly affects the nervous
system and the adrenal glands, which are small glands located on top of each
kidney. Abetalipoproteinemia is also a kind of Adrenoleukodystrophy
(Adrenomyeloneuropathy/ Schilder-Addison Complex) Bassen-Kornzweig syndrome is
a rare disease passed down through families in which a person is unable to
fully absorb dietary fats through the intestines. The disease is caused by a
defect in gene that tells the body to create lipoproteins. It is sympotomized
by curvature of spine, muscle weakness, decrease of vision over time. Treatment
involves large doses of vitamin supplements containing fat-soluble
vitamins."
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adrenoleukodystrophy
- Pipeline Review, H1 2018, provides comprehensive information on the
therapeutics under development for Adrenoleukodystrophy (Genetic Disorders),
complete with analysis by stage of development, drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The
Adrenoleukodystrophy (Genetic Disorders) pipeline guide also reviews of key
players involved in therapeutic development for Adrenoleukodystrophy
(Adrenomyeloneuropathy/ Schilder-Addison Complex) and features dormant and
discontinued projects. The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in Phase III,
Phase II, Phase I and Preclinical stages are 3, 2, 3 and 4 respectively.
Similarly, the Universities portfolio in Phase II, Phase I and Preclinical
stages comprises 1, 1 and 1 molecules, respectively.
Adrenoleukodystrophy
(Genetic Disorders) pipeline guide helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage. The guide is built using data and information sourced
from Global Markets Direct's proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic tracking
processes ensure that the most recent developments are captured on a real time
basis.
The
pipeline guide provides a snapshot of the global therapeutic landscape of
Adrenoleukodystrophy (Genetic Disorders).
The
pipeline guide reviews pipeline therapeutics for Adrenoleukodystrophy (Genetic
Disorders) by companies and universities/research institutes based on
information derived from company and industry-specific sources.
The
pipeline guide covers pipeline products based on several stages of development
ranging from pre-registration till discovery and undisclosed stages.
The
pipeline guide features descriptive drug profiles for the pipeline products
which comprise product description, descriptive licensing and collaboration
details, R&D brief, MoA & other developmental activities.
The
pipeline guide reviews key companies involved in Adrenoleukodystrophy (Genetic
Disorders) therapeutics and enlists all their major and minor projects.
The
pipeline guide evaluates Adrenoleukodystrophy (Genetic Disorders) therapeutics
based on mechanism of action (MoA), drug target, route of administration (RoA)
and molecule type.
The
pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The
pipeline guide reviews latest news related to pipeline therapeutics for
Adrenoleukodystrophy (Genetic Disorders)
To know more, click on the link below:
Related Reports:
Contact Us:
Ken
Research
Ankur
Gupta, Head Marketing & Communications
0124-4230204